Global Cancer Vaccines Clinical Pipeline 2015 by Phase, Indication, Company & Country

Mar 01, 2016, 12:10 ET from Research and Markets

DUBLIN, March 1, 2016 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/4b9b86/global_cancer) has announced the addition of the "Global Cancer Vaccine Market & Clinical Trial Insight" report to their offering.

The cancer vaccines have revolutionized the present views and methodologies of cancer treatment. As a result of which plenty of biotech companies are exploring the field of cancer vaccines. This has caused the development of numerous cancer vaccines for numerous types of cancer. Pharmaceutical companies are using these vaccines for clinical trials; few of them are already available to the patients across the world. The US and EU were the first markets to approve the cancer vaccines for therapeutic usage. As compared to rest of the world, commercialization and development in these regions have already made a significant progress.

The attractiveness for cancer vaccines has increased in past few years due to their characteristic properties like less side effects, low toxicity and high specificity. Besides, innovations related to novel delivery methods have also made them a lucrative option. Unlike traditional methods, they can be used for targeting the sub-group of cancers without effecting normal cells. Another factor in their favor is their high efficacy levels as compared to the presently available cancer therapeutics.

The market size of cancer vaccines category is many fold smaller than other cancer therapeutics categories. Due to nascent stages of industry-life cycle and late introduction in market has decreased their overall share. To tap this cancer market category, many global companies are actively investing in cancer vaccine development. The market penetration is expected to increase with the competition among various pharmaceutical companies to get a larger portion of this market category.

The cancer vaccines have to go through a long journey before enjoying the status of blockbuster drug. Presently, they have achieved a lot of success in both therapeutic and preventive field. However, inclination of market and researchers seems to be more towards the preventive category of cancer vaccines. For therapeutic side, it should be noted that novel methods for cancer eradication has been made. The future of cancer vaccines looks optimistic and plenty of cancer vaccines will hit the shelf in coming years.

"Global Cancer Vaccine Market & Clinical Trial Insight" Report Highlights:

- Global Cancer Market Overview

- Emergence of Personalized Cancer Vaccines

- Platforms for Cancer Vaccines Delivery

- Mechanism of Cancer Vaccines

- Global Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country

- Global Cancer Vaccine Clinical Pipeline: 298 Vaccines

- Marketed Cancer Vaccines: 15 Vaccines

- Regulatory Framework for Cancer Vaccines Development & Marketing

Key Topics Covered:

1. Introduction to Cancer Vaccines

2. Mechanism of Cancer Vaccines 2.1 Idiotype Cancer Vaccine Mechanism 2.2 Cellular Cancer Vaccines Mechanism 2.3 Ganglioside Antigens based Cancer Vaccines Mechanism 2.4 Peptide Cancer Vaccine Mechanism 2.5 Tumor Host Interaction Cancer Vaccine Mechanism

3. Adjuvants Therapy for Cancer Vaccines

4. Global Cancer Vaccines Market Overview 4.1 Current Market Scenario 4.2 Global Cancer Vaccine Drug Pipeline by Indication

5. Emergence of Personalized Cancer Vaccines

6. Public HPV Cancer Vaccination Program

7. Global Cancer Vaccines Market Dynamics

7.1 Favorable Market Parameters

7.1.1 Potential Demand for Cancer Vaccines

7.1.2 Public Cancer Vaccination Program

7.1.3 Advancements in Development Technology

7.1.4 Personalized Cancer Vaccines

7.1.5 Myriad of Demographs for Cancer Vaccine Development

7.2 Commercialization Challenges

8. Global Cancer Vaccine Market Future Outlook

9. Bladder Cancer Vaccine Clinical Pipeline Insight by Company & Phase

9.1 Phase-II

10. Blood Cancer Vaccine Clinical Pipeline Insight by Company & Phase 10.1 Research till Preregistration

11. Brain Cancer Vaccine Clinical Pipeline Insight by Company & Phase

11.1 Preclinical Till Phase-III

12. Breast Cancer Vaccine Clinical Pipeline Insight by Company & Phase 12.1 Preclinical till Phase-III

13. Cancer Vaccine Clinical Pipeline Insight by Company & Phase

13.1 Research till Phase-II

14. Cervical Cancer Vaccine Clinical Pipeline Insight by Company & Phase 14.1 Phase-II

15. Colorectal Cancer Vaccine Clinical Pipeline Insight by Company & Phase

15.1 Preclinical till Preregistration

16. Head and Neck Cancer Vaccine Clinical Pipeline Insight by Company & Phase 16.1 Preclinical till Phase-I/II

17. Liver Cancer Vaccine Clinical Pipeline Insight by Company & Phase

17.1 Phase-I till Phase-II

18. Lung Cancer Vaccine Clinical Pipeline Insight by Company & Phase 18.1 Preclinical till Phase-III

19. Oesophageal Cancer Vaccine Clinical Pipeline Insight by Company & Phase

19.1 Phase-III

20. Ovarian Cancer Vaccine Clinical Pipeline Insight by Company & Phase 20.1 Preclinical till Phase-III

21. Pancreatic Cancer Vaccine Clinical Pipeline Insight by Company & Phase

21.1 Reseach till Phase-III

22. Prostate Cancer Vaccine Clinical Pipeline Insight by Company & Phase 22.1 Preclinical till Phase-III

23. Renal Cancer Vaccine Clinical Pipeline Insight by Company & Phase

23.1 Phase-I till Phase-III

24. Sarcoma Vaccine Clinical Pipeline Insight by Company & Phase 24.1 Phase-II

25. Skin Cancer Vaccine Clinical Pipeline Insight by Company & Phase

25.1 Preclinical till Phase-III

26. Solid Tumours Vaccine Clinical Pipeline Insight by Company & Phase 26.1 Preclinical till Phase-II

27. Multiple Cancer Vaccine Clinical Pipeline Insight by Company & Phase

27.1 Preclinical till Phase-III

28. Marketed Cancer Vaccine Clinical Insight by Company & Indication 28.1 Bladder Cancer 28.1.1 BCG Bladder Cancer Vaccine (Immucyst® & TheraCys®) 28.1.2 Bladder Cancer Vaccine (PACIS®) 28.1.3 Bladder Cancer Vaccine - Organon Teknika

28.2 Cervical Cancer

28.2.1 Human Papillomavirus Vaccine Recombinant Bivalent (Cervarix®)

28.3 Lung Cancer 28.3.1 BV NSCLC 001 28.3.2 Cadi 05 (Immuvac® & Mycidac-C) 28.3.3 Racotumomab (Vaxira®)

28.4 Pancreatic Cancer

28.4.1 Tertomotide (LucaVax)

28.5 Prostate Cancer 28.5.1 Sipuleucel-T (Provenge®)

28.6 Renal Cancer

28.6.1 Renal Cancer Vaccine (Reniale®)

28.6.2 Vitespen (Oncophage®)

28.7 Skin Cancer 28.7.1 Melanoma Vaccine (MVax®) 28.7.2 Melanoma Vaccine (Melacine®)

28.8 Multiple Cancer

28.8.1 Human Papillomavirus Vaccine 9-Valent (V503) (GARDASIL®9)

28.8.2 Human Papillomavirus Vaccine Quadrivalent (Gardasil® & Silgard®)

29. Discontinued & Suspended Cancer Vaccine Drug Clinical Pipeline Insight 29.1 No Development Reported 29.2 Discontinued 29.3 Suspended

30. FDA Regulatory Framework for Cancer Vaccines Development & Marketing

30.1 Considerations for both Early and Late Phase Clinical Trials

30.1.1 Patient Population

30.1.2 Monitoring the Immune Response

30.1.3 Biomarkers as Evidence Of Efficacy

30.1.4 Adjuvants Used To Stimulate Immune Response

30.1.5 Multi-Antigen Vaccines

30.1.6 Disease Progression/Recurrence Immediately Or Shortly After The Initial Administration Of Cancer Vaccines

30.1.7 Concomitant and Subsequent Therapies

30.2 Considerations for Early Phase Clinical Trials 30.2.1 Starting Dose and Dosing Schedule 30.2.2 Booster and Maintenance Therapy 30.2.3 Dose Escalation 30.2.4 Single-Arm versus Randomized Phase 2 Trials In Early Development

30.3 Considerations for Late Phase Clinical Trials

30.3.1 Safety Profile from Early Phase Clinical Trials

30.3.2 Endpoints

30.3.3 Statistical Issues

30.3.4 Control Issues

30.3.5 Delayed Vaccine Effect

30.3.6 Autologous Vaccine Trials

30.3.7 Accelerated Approval Regulations

31. Competitive Landscape: Business Overview & Product Pipeline 31.1 Advaxis 31.2 AVAX Technologies 31.3 Celldex Therapeutics 31.4 Dendreon Corporation 31.5 Galena Biopharma 31.6 GlaxoSmithKline 31.7 ImmunoCellular Therapeutics 31.8 ImmunoGen 31.9 Inovio Pharmaceuticals 31.10 KAEL-GemVax 31.11 Liponova 31.12 MedImmune 31.13 Merck 31.14 NeoStem Oncology 31.15 NewLink Genetics 31.16 Northwest Biotherapeutics 31.17 Novartis 31.18 Peregrine Pharmaceuticals 31.19 Recombio 31.20 Roche 31.21 Sanofi 31.22 Seattle Genetics 31.23 Valeant Pharmaceuticals

For more information visit http://www.researchandmarkets.com/research/4b9b86/global_cancer

Media Contact:

Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

 

SOURCE Research and Markets



RELATED LINKS

http://www.researchandmarkets.com